SuperworthSight Sciences profit margin SGHT
Gross, operating and net profit as a share of revenue over the last twelve months, from 2023.
- Net margin, 12 months
- −35.7%
- Operating margin, 12 months
- −33.4%
- Net margin on a year earlier
- +28.5 pts
- Peer median
- 7.8%
Over the twelve months to Jun 30, 2026, Sight Sciences kept −35.7% of its revenue as net profit, with an operating margin of −33.4% and a gross margin of 88.0%.
The median for 10 medical instruments and supplies stocks of a similar size is 7.8%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −49.7% | −48.0% | 86.2% |
| FY2024 | −64.5% | −63.3% | 85.5% |
| FY2023 | −68.5% | −70.7% | 85.3% |
| FY2022 | n/a | n/a | 82.7% |
| FY2021 | n/a | n/a | 82.4% |
| FY2020 | n/a | n/a | 66.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −35.7% | +28.5 pts | −33.4% | |
| Q1 FY26 | −46.8% | +16.4 pts | −44.8% | |
| Q4 FY25 | −49.7% | +14.8 pts | −48.0% | |
| Q3 FY25 | −60.6% | +2.7 pts | −59.6% | |
| Q2 FY25 | −64.2% | +1.7 pts | −63.8% | |
| Q1 FY25 | −63.2% | +3.9 pts | −63.6% | |
| Q4 FY24 | −64.5% | +4.0 pts | −63.3% | |
| Q3 FY24 | −63.3% | +11.2 pts | −62.5% | |
| Q2 FY24 | −65.9% | +21.1 pts | −65.4% | |
| Q1 FY24 | −67.2% | n/a | −66.8% | |
| Q4 FY23 | −68.5% | n/a | −70.7% | |
| Q3 FY23 | −74.6% | n/a | −76.3% |
Against its peers
Companies in Medical - Instruments & Supplies nearest Sight Sciences' size, closest first, today.
| Company | Profit margin |
|---|---|
| SGHTSight Sciences | −35.7% |
| TCMDTactile Systems Technology | 7.1% |
| MDXGMimedx | 1.8% |
| EMBCEmbecta | 8.6% |
| MOVMovado | 6.0% |
| INFUInfuSystem | 6.0% |
| UTMDUtah Medical Products | 29.0% |
| IRMDIradimed | 26.7% |
| STAAStaar Surgical | 1.1% |
| PDEXPro DEX | 17.6% |
| BVSBioventus | 9.4% |
| Peer median | 7.8% |
Where Sight Sciences ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Sight Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.